Assembly Biosciences (ASMB) Expected to Release Quarterly Earnings on Wednesday

Assembly Biosciences (NASDAQ:ASMB) is anticipated to release its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Assembly Biosciences to post earnings of ($0.70) per share and revenue of $8.5990 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.11. The firm had revenue of $8.21 million for the quarter, compared to analysts’ expectations of $9.27 million. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%. On average, analysts expect Assembly Biosciences to post $2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Assembly Biosciences Trading Up 1.2%

Shares of Assembly Biosciences stock opened at $25.88 on Wednesday. The firm has a market capitalization of $411.31 million, a PE ratio of -232.82 and a beta of 1.08. Assembly Biosciences has a 12 month low of $16.90 and a 12 month high of $39.71. The business’s 50-day moving average price is $25.93 and its 200-day moving average price is $27.60.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. RA Capital Management L.P. bought a new stake in shares of Assembly Biosciences in the third quarter worth $26,122,000. Paradigm Biocapital Advisors LP bought a new position in Assembly Biosciences in the fourth quarter valued at about $22,625,000. Parkman Healthcare Partners LLC bought a new position in Assembly Biosciences in the third quarter valued at about $6,425,000. Vanguard Group Inc. boosted its position in Assembly Biosciences by 97.8% in the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after purchasing an additional 248,287 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new position in Assembly Biosciences in the fourth quarter worth about $5,476,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ASMB shares. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Friday, July 17th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a report on Monday, May 4th. Wall Street Zen downgraded shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Mizuho set a $45.00 price objective on shares of Assembly Biosciences and gave the stock an “outperform” rating in a report on Monday, June 15th. Finally, Guggenheim reiterated a “buy” rating and set a $43.00 target price on shares of Assembly Biosciences in a research note on Thursday, May 28th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $44.00.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.